ONCOLife Issues
Featured Articles
Trending Articles
FDA Approves Agilent’s PD-L1 Test to Guide KEYTRUDA Use in Esophageal and GEJ Carcinoma
FDA & EMA | 28 March 2026
New Protein Modification Linked to IDH-Mutant Cancers Opens Therapeutic Possibilities
ONCOLife | 26 March 2026
BioNTech Showcases Promising Bispecific and ADC Data in Lung Cancer at ELCC 2026
ONCOLife | 25 March 2026
Sunvozertinib Outperforms Chemo in First-Line EGFR Exon 20 Insertion NSC Lung Cancer
ONCOLife | 22 March 2026
Magnetic Nanoparticle-Guided Hyperthermia Opens a New Path for Advanced Solid Tumors
ONCOLife | 23 March 2026
TG Therapeutics Secures $500M to Advance BRIUMVI in Relapsing Multiple Sclerosis
Biotech | 20 March 2026
Targeted Bladder Cancer Therapy Erda-iDRS Achieves 89% Response Rate and PDC
ONCOLife | 15 March 2026
Atirmociclib Reduces Progression Risk by 40% in CDK4/6 Metastatic Breast Cancer
ONCOLife | 17 March 2026
TALAPRO-3 Trial Supports Early Use of Talazoparib in HRR+ mCS Prostate Cancer
ONCOLife | 20 March 2026
FDA Approves Nivolumab-AVD as First Immunotherapy Combination for Hodgkin Lymphoma
FDA & EMA | 20 March 2026
Abenacianine Enters Phase 3 to Enhance Real-Time Tumor Detection in Lung Surgery
ONCOLife | 19 March 2026
CellCarta Secures Global Exclusivity for Aspyre Lung to Advance Lung Cancer Testing
Cancer | 18 March 2026
Designing Digital Healthcare Systems for the Future of Patient-Centered Care
Digital Health
4 March 2026
Amivantamab Plus Chemotherapy Shows Promising Responses in Colorectal Cancer
Clinical Trials
11 January 2026
Novartis Expands US Radioligand Manufacturing With $23 Billion Investment in Florida
Pharma
9 January 2026
TRBC2-Specific ADC Shows Robust Efficacy in T-Cell Lymphomas and Leukemias
Clinical Trials
24 December 2025
Engineered Oncolytic Virus Reprograms Immunity and Extends Survival in Brain Cancer
ONCOLife
20 December 2025
FDA Approves First Subcutaneous Amivantamab Plus Lazertinib for EGFR+ Lung Cancer
FDA & EMA
18 December 2025
Platinum-Free PADCEV Plus Pembrolizumab Improves Survival in MI Bladder Cancer
Clinical Trials
18 December 2025
FDA Approves T-DXd Plus Pertuzumab as a First-Line Standard in HER2+ Breast Cancer
FDA & EMA
16 December 2025
Less Toxic, More Effective: RW Evidence Supports Reduced Immunotherapy Dose in Melanoma
Clinical Trials
14 December 2025
Teclistamab plus Daratumumab Achieves an 83% Risk Reduction in R/R Multiple Myeloma
Clinical Trials
10 December 2025
FDA Approves AKEEGA for BRCA2+ Prostate Cancer as the First Precision Therapy
FDA & EMA
12 December 2025